ESOPHAGEAL ADENOCARCINOMA
Clinical trials for ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Treat gut cancers – but study halted early
Disease control TerminatedThis study tested two drugs, ulixertinib and hydroxychloroquine, in 47 adults with advanced gastrointestinal cancers that have specific gene mutations (MAPK pathway). The goal was to see if the combination could shrink tumors or slow cancer growth. The trial was terminated early,…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Jun 22, 2026 12:03 UTC
-
Experimental cancer pill targets rare mutation, but trial halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called PRT7732 in 42 people with advanced solid tumors that have a SMARCA4 mutation. The goal was to check safety, find the right dose, and see if it shrinks tumors. However, the trial was terminated, so full results are not…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC